Although monotherapy with an anti-PD-1 antibody and combination therapy with cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antibodies have shown anti-tumour activity in advanced sarcomas, the response rate remains modest less than 20%8,9. Here, CTLA4 is linked to sarcoma.